

Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease

Patrick J. Tighe^{1*}, Richard A. Urbanowicz^{1,2}, C. Lucy Fairclough¹, C. Patrick McClure^{1,2}, Brian J. Thomson^{3,4}, Nancy Gomez¹, Joseph G. Chappell^{1,2}, Theocharis Tsoleridis^{1,2}, Matthew Loose^{1,5}, Matthew Carlile^{1,5}, Christopher Moore^{1,5}, Nadine Holmes^{1,5}, Fei Sang^{1,5}, Divyateja Hrushikesh⁶, Gemma Clark⁷, Nigel Temperton⁸, Tim Brooks⁹, Jonathan K. Ball^{1,2,4}, William L. Irving^{1,2,4} & Alexander W. Tarr^{1,2,4*}

¹School of Life Sciences, Faculty of Medicine and Health Sciences, The University of Nottingham, Nottingham, UK

²Wolfson Centre for Global Virus Infections, The University of Nottingham, Nottingham, UK

³School of Medicine, Faculty of Medicine and Health Sciences, The University of Nottingham, Nottingham, UK

⁴NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK

⁵DeepSeq, Faculty of Medicine and Health Sciences, The University of Nottingham, Nottingham, UK

⁶Department of Clinical Chemistry, Nottingham University Hospitals NHS Trust, Nottingham, UK

⁷Department of Microbiology, Nottingham University Hospitals NHS Trust, Nottingham, UK

⁸Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and University of Greenwich, Kent, UK


⁹Rare & Imported Pathogens Laboratory, Public Health England, Porton Down, Salisbury, UK

*Correspondence patrick.tighe@nottingham.ac.uk; alex.tarr@nottingham.ac.uk

Supplementary material

Development of specific anti-SARS-CoV-2 S1 and N immunoassays. The ELISA assay was optimised for quantitative detection of antibodies to SARS-CoV-2 spike (S1 subunit) and nucleocapsid proteins. Routine diagnostic samples taken from confirmed (RT-PCR positive) SARS-CoV-2 infections sampled in the first week of April 2020 were inactivated and used in these immunoassays. Strong reactivity to the S1 subunit of spike (Supplementary Figure 1A) and nucleocapsid (Supplementary Figure 1B) was observed for some, but not all, samples. Serial titration of these samples identified 1:600 dilution as providing the greatest resolving power and quantitative discrimination of sero-reactivity. Further experiments were performed with 128 samples from a collection of sera screened for hepatitis C virus [1], retrieved from surplus routine sera taken from patients attending the Nottingham University Hospitals Trust hepatitis clinic during August 2019. Performing the assay at 1:600, samples from this cohort reliably provided low signal with this assay, with only one sample providing strong signal for reactivity to the nucleocapsid protein (Supplementary Figure 1C). Having determined the conditions delivering maximal sensitivity and specificity, validation against the commercially available Euroimmun S1 serology assay using a subset of samples was performed by the Public Health England laboratories. Concordance between the two assays with this set of samples was 100% (data not shown). In addition, our assays did not suffer from the same level of saturation of the ELISA signal that was observed with the Euroimmun anti-spike assay and Roche anti-N assay, providing enhanced quantitative assessment of the differences in antibody binding signal for hospitalised patients.

Supplementary Figure 1:



Supplementary Figure 1. Optimisation of serological assays for SARS-CoV-2 Spike S1 subdomain and nucleocapsid proteins. Serial dilutions of confirmed SARS-CoV-2 infected sera were analysed by ELISA for A) anti-spike S1 domain (spike S1) and B) anti-nucleocapsid (N) specific IgGs. C) Sera collected in August 2019 for routine virological analysis (n=128) were assessed by ELISA for IgG antibodies to the aforementioned target molecules. Lines indicate the median of the respective signals determined (Median =0.1495 for NC, 0.1592 for Spike S1)

[1] Mohsen AH, Trent HCVSG. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. *Gut*. 2001;48:707-13.